- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Lilly confident of FDA approval for Amyvid, Lechleiter says
March 9, 2011
Bloomberg NewsEli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify
plaque in the brain associated with Alzheimer’s disease.
MoreLilly's Bydureon falls short of competitor in study
March 3, 2011
Bloomberg NewsBydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t
control the disease better than Novo Nordisk A/S’s Victoza in a study.
MoreUPDATE: Bioanalytical researcher opening lab in Indianapolis
March 1, 2011
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the
workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of
a partnership.
MoreEli Lilly neuroscience chief resigns
February 25, 2011
J.K. WallDavid Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according
to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in
late-stage human testing to treat Alzheimer’s and depression.
MoreUPDATE: Lilly settles pollution suit for $337,500
February 24, 2011
Scott OlsonA complaint filed Wednesday by the U.S. government says Lilly's plant on South Harding Street is emitting high levels of acetonitrile
and methanol, considered hazardous air pollutants by the EPA.
MoreLilly looks to double pipeline size again
February 23, 2011
J.K. WallIndianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to
60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this
alternative pipeline.
MoreLilly's master plan for downtown (real estate)
February 19, 2011
Cory SchoutenAs Eli Lilly and Co. outsources work and sheds unnecessary properties, it is making moves with surplus real estate that could
establish the strongest physical connection between Lilly and downtown since the company was founded at Pearl and Meridian
streets 135 years ago.
MoreEmerging markets give Lilly hope in patent crunch
February 19, 2011
J.K. WallIn a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting
the drugmaker to pour money into emerging markets in an attempt to prop up revenue.
MoreLilly takeover provision to be voted on again
February 11, 2011
Scott OlsonThe effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly's board is on the agenda
of the company's April 18 annual meeting.
MoreLilly names new head of cancer drug business
February 11, 2011
Associated PressEli Lilly and Co. on Friday named company insider Sue Mahony as president of its cancer drug business.
MoreArcadia reports smaller loss on increased revenue
February 9, 2011
The Indianapolis-based health care company lost $2.3 million on revenue of $26.2 million in its third fiscal quarter.
MoreRecent successes don't change Lilly's outlook
February 9, 2011
J.K. WallEli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past
18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have
paltry sales prospects.
MoreLilly collaboration with outside researchers yields first deal
February 8, 2011
Chris O'MalleyEli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz
said it's just the first of many such collaborations.
MoreEndocyte again changes terms of public offering
February 4, 2011
IBJ Staff and Bloomberg NewsThe West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more
than previously announced, but at a lower price of $6 each.
MoreLilly, Bristol-Myers halt enrollment in lung-cancer trial
February 2, 2011
J.K. WallEli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung
cancer drug over concerns about patients developing blood clots.
MorePotential competitor to Lilly drug shows promise in study
February 2, 2011
IBJ Staff and Bloomberg NewsSanofi-Aventis's experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective
as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.'s twice-daily medicine Byetta, a study found.
MoreMarcadia may fetch up to $537 million in sale
February 2, 2011
J.K. WallThe December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for
the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes
medicines.
MoreMini Thin marketer slapped with suit
January 29, 2011
Kathleen McLaughlinA Carmel man whose Mini Thin dietary supplement was sold through convenience stores nationwide before the government banned
its active ingredient now faces allegations of bankruptcy fraud.
MoreLilly product gets boost; Wall Street yawns
January 26, 2011
J.K. WallEli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease,
but so far analysts are unimpressed.
MoreHead of Lilly's oncology unit resigning
January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
MoreVanderbilt rejected by high court on Cialis patents
January 24, 2011
Bloomberg NewsSupreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against
Eli Lilly's Icos subsidiary.
More21st Century Fund pockets a payoff from sale
January 22, 2011
Chris O'MalleyThe state’s principal fund investing in high-tech companies has reached a milestone—for the first time recouping
all the money it granted an emerging company, and then some.
MoreLilly seeks to block imports of cancer drug copy
January 21, 2011
Bloomberg NewsThe local drugmaker told the International Trade Commission on Thursday that the generic version of Gemzar violates its patent
on the process for making the active ingredient.
MoreLilly imaging drug fails to win FDA panel's backing
January 21, 2011
Bloomberg NewsEli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA
advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results
of brain scans are read consistently, they said.
MoreDown on luck, Lilly finds comfort in pets
January 19, 2011
J.K. WallEli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Laura-the festivals and tastings are free. What does is strengthen the sense of community with activities. What are those empty lots doing for the Village? it's sad you can't see the good that this progress can do for the area. No one is requiring anyone to shop there. I guess you'd rather see a Dollar store move in or no, we'd rather see the property stand empty b/c change is out of the question.
Read down to the part about Brizzi. Someone needs to subpoena his "purchases" of Red RockPictures and Cellstar and his corresponding bank records, I mean c'mon, I'd like to see his alcohol usage records, too. http://diana-vice.blogspot.com/2011_01_01_archive.html
Wonder if my neighborhood can advertise our "retention" pond and act like it is a beach too?
a new record at the '11 salebration until they realized that it was a futile effort to get their crapwagon moter and crapwagon car up speed. And then they just quietly slunk off into the night and never spoke of it again. Nothing to see here folks.
millions for putting a company's bumper sticker on one of its Lolas. But you gotta take what you can get.